Premium
Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder
Author(s) -
Kelsey Jeffrey E.
Publication year - 2000
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/1520-6394(2000)12:1+<81::aid-da11>3.0.co;2-f
Subject(s) - tolerability , venlafaxine , generalized anxiety disorder , major depressive disorder , psychiatry , population , anxiety , psychology , anxiety disorder , major depressive episode , medicine , mood , antidepressant , adverse effect , environmental health
Generalized anxiety disorder (GAD) is a common and chronic disorder with a low rate of spontaneous remission. A complication in treatment selection is the high rates of co‐morbid major depressive disorder in this population. A number of treatments exist to treat GAD. The most recent medication to gain an indication for GAD is venlafaxine XR, a serotonin/norepinephrine reuptake inhibitor that is also approved for the treatment of major depressive disorder. More than 2,000 patients with GAD have been studied in outpatient trials of venlafaxine XR with demonstrated efficacy, tolerability and safety of this compound. This article reviews these studies, both short term and longer (6 month) continuation trials. The response to venlafaxine XR in this population, combined with good tolerability, makes this agent an appropriate first‐line medication for GAD. In general, treatment with antidepressants, though associated with a longer onset of action than benzodiazepines, does not produce physiological dependency, and is useful in a patient population with a high prevalence of mood disorders. Depression and Anxiety, Volume 12, Supplement 1:81–84, 2000. © 2000 Wiley‐Liss, Inc.